Soleus Capital Management, L.P. Nurix Therapeutics, Inc. Transaction History
Soleus Capital Management, L.P.
- $1.44 Billion
- Q4 2024
A detailed history of Soleus Capital Management, L.P. transactions in Nurix Therapeutics, Inc. stock. As of the latest transaction made, Soleus Capital Management, L.P. holds 2,102,833 shares of NRIX stock, worth $35.5 Million. This represents 2.76% of its overall portfolio holdings.
Number of Shares
2,102,833
Previous 1,065,834
97.29%
Holding current value
$35.5 Million
Previous $23.9 Million
65.57%
% of portfolio
2.76%
Previous 2.03%
Shares
11 transactions
Others Institutions Holding NRIX
# of Institutions
185Shares Held
70.6MCall Options Held
318KPut Options Held
42.4K-
Black Rock Inc. New York, NY6.82MShares$115 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.35MShares$73.3 Million0.0% of portfolio
-
Redmile Group, LLC San Francisco, CA4.19MShares$70.7 Million6.18% of portfolio
-
Baker Bros. Advisors LP New York, NY3.88MShares$65.5 Million0.81% of portfolio
-
Wellington Management Group LLP Boston, MA3.59MShares$60.5 Million0.01% of portfolio
About Nurix Therapeutics, Inc.
- Ticker NRIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 47,147,800
- Market Cap $795M
- Description
- Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies...